November 14th, 2011
PALLAS: Poor Results for Dronedarone in Permanent AF
Larry Husten, PHD
After a brief announcement earlier this year that the trial had been terminated early, the full results of PALLAS (Permanent Atrial Fibrillation Outcomes Study Using Dronedarone on Top of Standard Therapy) have now been presented at the AHA and published simultaneously in the New England Journal of Medicine. PALLAS shows that dronedarone (Multaq, Sanofi) should not be used in patients […]
July 7th, 2011
Dronedarone (Multaq) Study for Permanent AF Stopped Early
Larry Husten, PHD
The PALLAS trial of dronedarone (Multaq) for permanent AF has been stopped early, according to a press release issued by Sanofi. PALLAS (Permanent Atrial fibriLLAtion outcome Study using Dronedarone on top of standard therapy) was a double-blind, placebo-controlled, phase IIIb trial of dronedarone in patients with permanent AF. The company said the discontinuation of the trial […]
NEJM Journal Watch — Recent Cardiology Articles- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?
- A Randomized Trial of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation
- An Early Look at a Novel Intranasal Loop Diuretic